If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-28. Numbers and descriptions here follow the published literature rather than marketing material.
监管记录显示,特沙莫瑞林于 2010 年在美国首次获得批准,用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验,而非体重或瘦体重的普遍改善。后续出现了不同制剂版本,但其核心适应症保持一致。关于长期心血管结局和死亡率影响,现有证据仍不充分。
在临床研究之外,特沙莫瑞林常被讨论为生长激素分泌促进剂,但这一说法需要限定。它并不等同于生长激素本身,也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力,另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中,尚未形成统一结论。
特沙莫瑞林是一种合成肽,其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰,这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂,可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物,而非小分子化合物。
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成肽 | 含 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 用于抵抗二肽基肽酶 IV 降解 |
| 首次批准 | 2010 年,美国 | 用于 HIV 相关脂肪营养不良 |
| 作用靶点 | 生长激素释放激素受体 | 位于垂体前叶 |
| 主要研究终点 | 内脏脂肪变化 | 非总体重或瘦体重 |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
In the case of large pets, such as dogs and cats, freeze-drying is also the best way to capture the animal's expression as it looked in life (another important concern of owners). Freeze-drying equipment is costly and requires much upkeep. The process is also time-consuming; therefore, freeze-drying is generally an expensive method to preserve an animal. The drawback to this method is that freeze-dried mounts are extremely susceptible to insect damage. This is because they contain large areas of dried tissue (meat and fat) for insects to feed upon. Traditional mounts are far less susceptible because they contain virtually no residual tissues (or none at all). Regardless of how well a taxidermy mount is prepared, all taxidermy is susceptible to insect damage. Taxidermy mounts are targeted by the same beetles and fabric moths that destroy wool sweaters and fur coats and that infest grains and flour in pantries.
Operation Savannah accelerated the shift of SWAPO's alliances among the Angolan nationalist movements. Until August 1975, SWAPO was theoretically aligned with the MPLA, but in reality PLAN had enjoyed a close working relationship with UNITA during the Angolan War of Independence. In September 1975, SWAPO issued a public statement declaring its intention to remain neutral in the Angolan Civil War and refrain from supporting any single political faction or party. With the South African withdrawal in March, Sam Nujoma retracted his movement's earlier position and endorsed the MPLA as the "authentic representative of the Angolan people". During the same month, Cuba began flying in small numbers of PLAN recruits from Zambia to Angola to commence guerrilla training. PLAN shared intelligence with the Cubans and FAPLA, and from April 1976 even fought alongside them against UNITA. FAPLA often used PLAN cadres to garrison strategic sites while freeing up more of its own personnel for deployments elsewhere. The emerging MPLA-SWAPO alliance took on special significance after PLAN was wracked by a mutiny in Western Province, Zambia between March and April 1976, known as the Shipanga Affair. Relations between SWAPO and the Zambian government were already troubled due to the fact that the growing intensity of PLAN attacks on the Caprivi often provoked retaliatory SADF raids into Zambia.
== Function == The primary function of DPEP1 is to hydrolyze various dipeptides in renal metabolism. Specifically, it has been found to hydrolyze glutathione and its conjugates such as leukotriene D (Kozak and Tate, 1982). Several pieces of evidence suggest that DPEP1 is also responsible for the hydrolysis of the beta-lactam ring of various THM-class antibiotics, such as penem and carbapenem (Campbell et al., 1984). First, the metabolism of these THM-class antibiotics is known to be localized in the kidney, specifically by a membrane-bound protein. Second, the metabolism of these antibiotics is significantly hindered when the zinc concentration is altered, suggesting the enzyme responsible for the drugs’ metabolism is a zinc-metalloenzyme. Finally, when DPEP1 was experimentally added to penem and carbapenem antibiotics in vitro, the resulting products were structurally identical to their respective metabolites found in an organism's urine (8). The hydrolysis of these antibiotics hinders their antibacterial capabilities, so information on the specific structure of DPEPI is highly sought after in order to find viable inhibitors that could be taken along with these antibiotics to make them more effective. Earlier, beta-lactamase enzymes were thought to occur only in bacteria, where their probable function was in protecting the organisms against the action of beta-lactam antibiotics. These antibiotics exhibit selective toxicity against bacteria but virtual inertness against many eukaryotic cells (Adachi et al., 1990).[supplied by OMIM]
wstd: weight of internal standard wspl: weight of sample n[H]std: the integrated area of the peak selected for comparison in the standard, corrected for the number of protons in that functional group n[H]spl: the integrated area of the peak selected for comparison in the sample, corrected for the number of protons in that functional group MWstd: molecular weight of standard MWspl: molecular weight of sample P: purity of internal standard
== Prevention == Prevention of atherosclerosis, which is a major risk factor of arterial embolism, can be performed e.g. by dieting, physical exercise and smoking cessation. In case of high risk for developing thromboembolism, antithrombotic medication such as warfarin or coumadin may be taken prophylactically. Antiplatelet drugs may also be needed.
Sources: en.wikipedia.org
== Career == He joined the Ethiopian Ministry of Foreign Affairs in 1978, serving as Ethiopia/EEC Relations Desk Officer. In 1983 he was mandated to the Diplomatic Mission in Brussels, with the title of economist. Berhanu participated in negotiations leading to the 1981 and 1985 extensions of the Lomé Convention – an agreement concerning international aid and trade between the African, Caribbean and Pacific countries and the European Union – as well as participating in the committees that managed this convention. In 1992 Berhanu returned to Addis Ababa to lead the Western European Division at the Ministry at the rank of Counselor, before taking on the role of Acting Director General for International Organisation and Economic Cooperation in 1993. Later that year he was promoted to Director General, and it was in this role that he represented Ethiopia at all of the Organisation of African Unity Council and Summit conferences held between 1992 and 2000, as well as the Economic Commission for Africa Ministerial Conferences held in this period, chaired the Economic and Social Council meeting of the African Economic Community in June 1998, and served as deputy leader of the Ethiopian delegation to the United Nations from 1993 to 2000. On 7 December 2000, he was appointed the Ethiopian ambassador to Russia. In February 2002, he was appointed Ambassador of Ethiopia to Sweden and concurrently Norway, Denmark, Finland and Iceland. In March 2006 he was appointed as Ambassador of Ethiopia to the United Kingdom, a position he held during 10 years. In 2016, H.E.
== Description == Senna occidentalis is a foetid shrub that typically grows to a height of 1–2 m (3 ft 3 in – 6 ft 7 in) and has softly-hairy branches and stems. Its leaves are pinnate, 150–170 mm (5.9–6.7 in) long on a petiole 20–40 mm (0.79–1.57 in) long, with three to seven pairs of broadly elliptic to egg-shaped leaflets 50–70 mm (2.0–2.8 in) long and 30–40 mm (1.2–1.6 in) wide, spaced 15–30 mm (0.59–1.18 in) apart. There is a sessile glands near the base of the petiole. The flowers are yellow and arranged on the ends of branchlets and in upper leaf axils in groups of two to four on a peduncle 2–5 mm (0.079–0.197 in) long, each flower on a pedicel 10–15 mm (0.39–0.59 in) long. The petals are up to 10 mm (0.39 in) long and there are six fertile stamens, the anthers varying in length from 4 to 6 mm (0.16 to 0.24 in) long, and four staminodes. Flowering occurs all year, and the fruit is a cylindrical pod 120–180 mm (4.7–7.1 in) long, about 3 mm (0.12 in) wide and slightly curved.
Many types of substances are known to interact with amphetamine, resulting in altered drug action or metabolism of amphetamine, the interacting substance, or both. Inhibitors of enzymes that metabolize amphetamine (e.g., CYP2D6 and FMO3) will prolong its elimination half-life, meaning that its effects will last longer. Amphetamine also interacts with MAOIs, particularly monoamine oxidase A inhibitors, since both MAOIs and amphetamine increase plasma catecholamines (i.e., norepinephrine and dopamine); therefore, concurrent use of both is dangerous. Amphetamine modulates the activity of most psychoactive drugs. In particular, amphetamine may decrease the effects of sedatives and depressants and increase the effects of stimulants and antidepressants. Amphetamine may also decrease the effects of antihypertensives and antipsychotics due to its effects on blood pressure and dopamine respectively. Zinc supplementation may reduce the minimum effective dose of amphetamine when it is used for the treatment of ADHD. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans. In general, there is no significant interaction when consuming amphetamine with food, but the pH of gastrointestinal content and urine affects the absorption and excretion of amphetamine, respectively. Acidic substances reduce the absorption of amphetamine and increase urinary excretion, and alkaline substances do the opposite.
== Toxicity == Short-term exposure to large amounts of PCP can cause harmful effects on the liver, kidneys, blood, lungs, nervous system, immune system, and gastrointestinal tract. Elevated temperature, profuse sweating, uncoordinated movement, muscle twitching, and coma are additional side effects. Contact with PCP (particularly in the form of vapor) can irritate the skin, eyes, and mouth. Long-term exposure to low levels, such as those that occur in the workplace, can cause damage to the liver, kidneys, blood, and nervous system. Finally, exposure to PCP is also associated with carcinogenic, renal, and neurological effects. The U.S. Environmental Protection Agency toxicity class classifies PCP in group B2 (probable human carcinogen).
Sources: en.wikipedia.org
特沙莫瑞林是国际非专利名称,指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽,序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。
监管批准集中于 HIV 感染相关的脂肪营养不良,目的是减少内脏脂肪。它未被批准用于普通肥胖或一般体重管理。不同国家的批准状态和标签范围可能不同。
长期心血管获益、死亡率影响以及停药后的持续性仍缺乏确证。部分研究提示 IGF-1 和血糖参数可能变化,但个体差异较大。这些开放问题需要更长期、更大规模的试验来回答。
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.